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Abstract: Plasma-derived exosomes of head and neck squamous cell carcinoma (HNSCC) patients
carry inhibitory factors mediating immune suppression. Separation of tumor-derived exosomes (TEX)
and non-TEX may assist in a better understanding of their respective parental cells. Here, we evaluate
the impact of TEX or hematopoietic-derived exosomes on immune suppression. We evaluated
apoptosis in CD8+ T cells, conversion of CD4+ T cells to regulatory T cells (Treg), and adenosine
production by TEX, non-TEX, or total exosomes. Exosome protein cargo was significantly higher in
total and CD45(−) exosomes from high stage compared to low stage patients. Furthermore, total and
CD45(−) exosomes of high stage patients induced more apoptosis in CD8+ T cells than their low stage
counterparts. CD69 suppression, a marker of reduced CD8+ T cell activation, was only mediated
by CD45(−) exosomes. All fractions induced Treg differentiation, defined by CD39 expression, but
only CD45(−) exosomes showed a stage-dependent conversion. CD45(−) exosomes produced higher
adenosine concentrations than CD45(+) exosomes, concluding that adenosine production measured
in total exosomes mainly derives from TEX. The presented results show significant induction of
immune suppression by TEX in HNSCC. This immunosuppressive effect supports the potential role
of exosomes as liquid biomarkers for disease stage and level of immune suppression.
Keywords: tumor-derived exosomes; immune regulation; HNSCC; liquid biopsy
1. Introduction
Head and neck squamous cell carcinomas (HNSCC) are highly aggressive and immunosuppressive
malignancies [1–3]. Even though there is a broad variety of therapeutic approaches available,
the outcome for advanced HNSCC is still very poor, with five-year survival rates being as low as
40% [4] due to early lymph node metastasis and locoregional recurrences [5].
One of the predictors for evasion of antitumor T cell response is an imbalance toward regulatory
T cells (Treg) as opposed to CD8+ effector T cells in the tumor microenvironment (TME) [6,7]. Treg,
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characterized by the expression of ectonucleoside triphosphate diphosphohydrolase-1 (CD39) [8],
not only play an important role in upholding this balance but also take part in the production of
immune-suppressive factors such as adenosine, a molecule hydrolyzed from adenosine triphosphate
(ATP) by CD39 and CD73 through an intermediate step via adenosine diphosphate (ADP) and 5′
adenosine monophosphate (AMP). It is degraded to inosine by adenosine deaminase (ADA), associated
with membrane anchor protein CD26 [8]. The presence of adenosine in the TME of HNSCC has
been linked to tumor progression and poor outcome [9]. Therefore, influencing factors on the T cell
balance are of great importance to broaden our understanding of tumor-host interaction. Among other
mechanisms contributing to immune suppression in the TME of HNSCC, extracellular vesicles (EVs)
such as exosomes have been identified as carriers and producers of immunosuppressive molecules.
Exosomes, as the smallest vesicles derived from the endocytic compartment, have a diameter between
30 and 150 nm and carry endocytic markers such as TSG 101 and tetraspanins [10,11]. Due to their
unique origin, they also carry molecular and genetic content that is representative of their parent cells
and present an important way of intercellular communication [12]. In plasma of HNSCC patients,
significantly more exosomes have been found than in healthy donors [13], correlating with tumor
stage and disease activity [14]. Through interaction with immune cells and non-immune cells in the
TME, exosomes are able to reprogram and alter cellular functions [15–17]. This can lead to suppression
of immune response and promotion of tumor growth [18]. With evolving methods for exosome
isolation from plasma, both characterization of molecular content by Western blot, flow cytometry,
or co-incubation assays [14,19] and separation into different subgroups have been achieved [20].
Plasma-derived exosomes originate from a multitude of different parent cells. Exosomes released
from immune cells and tumor cells are of special interest due to the unique insights they provide into
immune regulation and tumor status/progression in cancer patients. Previously the separation of
CD3(+) T cell-derived exosomes and CD3(−) exosomes, enriched in TEX, helped to gain insights into
exosomal signaling pathways of reprogrammed immune cells [20]. In patients with HNSCC, up to 50%
of all exosomes were CD3(+) and, therefore, T cell-derived, whereas only 20-30% of exosomes isolated
from healthy donors originate from T cells [20]. Both T cell-derived CD3(+) and non-T cell-derived
CD3(−) exosomes were able to induce apoptosis and suppress CD69 expression in activated CD8+ T
cells. However, the CD3(−) fraction induced higher levels of apoptosis in CD8+ T cells independent
of immunosuppressive content [14,20]. Furthermore, upregulation of CD39 on CD4+ T cells with
a consecutive increase of adenosine levels in the presence of exosomes from HNSCC cell lines and
patients has been shown [20,21]. These results emphasize the importance of TEX-enriched fractions
and immune cell-derived exosomes as influencing factors on immune response mechanisms in the
setting of cancer. In contrast to other cancer types such as melanoma (CSPG4) or prostate cancer (PSA),
there is no specific tumor marker available for the identification of HNSCC. Hence, separation of
TEX-only fractions presents a difficult task. To further characterize the effect of a higher TEX-enriched
fraction assuming a higher tumor load, we used a previously described immune capture approach.
As CD45 is ubiquitously expressed on all nucleated hematopoietic cells [22] including B and T cells but
not on squamous cells, we used this antigen for immune capture and enrichment of TEX. In this study,
we analyze the effect of CD45(−) TEX-enriched fraction on various T cell populations to understand
further the TME-modulating effects achieved by exosomes. Furthermore, we evaluate the potential
of plasma-derived exosome fractions as easily accessible liquid biomarkers for disease stage and
immune suppression.
2. Results
2.1. Clinicopathological Characteristics of HNSCC Patients
The clinicopathological data for 41 patients included in this study are listed in Table 1. Age ranged
from 43 to 85 years, with 71% of all patients being younger than 65 years. Patients were predominantly
male, and tumors were mainly located in the pharynx (52%), oral cavity (34%), and larynx (12%).
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All blood samples were collected prior to any therapy. Nineteen patients (46%) presented with Union
for International Cancer Control (UICC) low stage and 22 patients (54%) with UICC high stage disease.
Table 1. Patient characteristics.
Characteristics.
Patients (n = 41)
n %
Age (years)
≤ 65 29 71






Oral cavity 14 34
Pharynx 21 52
Larynx 5 12





















2.2. Characteristics of Plasma-Derived Exosomes
Exosomes isolated from plasma of HNSCC patients using mini size exclusion chromatography
(mini-SEC) met the criteria attributed to exosomes as specified by the MISEV 2018 guidelines [23]
(Figure 1). Transmission electron microscopy (TEM) confirmed vesicular morphology and vesicle
diameters between 30 and 220 nm (Figure 1A). Western blots of exosomes confirmed the presence of
TSG 101 as an endocytic marker (Figure 1B). Furthermore, CD45 was only present in CD45(+) and
total exosome samples, corroborating successful separation of exosomes into CD45(+) and CD45(−)
fractions (Figure 1B). Nanoparticle tracking analysis (NTA) confirmed a size range between 30 and 200
nm (Figure 1C).
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Figure 1. Exosome characterization. (A) Representative transmission electron microscopy pictures of 
CD45(−) (left) and total (middle and right) exosomes. (B) Western blot for detection of TSG 101, 
EpCAM and CD45 of total, CD45(−) and (+) exosomes from plasma of head and neck squamous cell 
carcinoma (HNSCC) patients (#1&2 high stage). Note that no CD45 signal was detected when using 
CD45(−) exosomes. Uncropped Western blots can be found at Figure S1. (C) Nanoparticle tracking 
analysis with ZetaView of total (left) and CD45(−) exosomes (right). Vesicles between 30 and 200 nm 
diameter were detected.  
2.3. Association of Exosomal Protein Levels with Clinicopathological Parameters 
Protein levels in exosome samples as a marker of tumor load were examined for association with 
tumor stage. Figure 2A shows a significantly higher protein content in exosomes of UICC high stage 
(III/IV) patients as opposed to UICC low stage (I/II) patients as demonstrated before [13]. The CD45(−) 
TEX-enriched fractions showed a higher exosome load in high stage compared to low stage patients, 
corresponding to a higher tumor load (Figure 2B). 
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2.3. Association of Exosomal Protein Levels with Clinicopathological Parameters
Protein levels in exosome samples as a marker of tumor load were examined for association with
tumor stage. Figure 2A shows a significantly higher protein content in exosomes of UICC high stage
(III/IV) patients as opposed to UICC low stage (I/II) patients as demonstrated before [13]. The CD45(−)
TEX-enriched fractions showed a higher exosome load in high stage compared to low stage patients,
corresponding to a higher tumor load (Figure 2B).
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Figure 2. Exosomal protein concentration. (A) Protein concentration of total exosomes from plasma 
of high and low stage HNSCC patients, n = 30 (B) CD45(−) exosome fraction of high and low stage 
patients, n = 29. p values were determined with Mann-Whitney test, with * p < 0,05, **** p < 0,0001. 
Bars represent mean with standard deviation (SD). 
2.4. Induction of Apoptosis in Activated CD8+ T Cells by Plasma-Derived Exosomes 
Induction of apoptosis in activated CD8+ T cells by plasma-derived exosomes of high and low 
stage patients was tested. Incubation with total exosomes of HNSCC patients induced significant 
levels of apoptosis compared to no-exosome controls, which was confirmed in this study (Figure 3A). 
When incubating activated CD8+ T cells with exosomes of UICC high and low stage patients, 
significant differences in apoptosis were visible. Total exosomes of high stage patients induced 
significantly more apoptosis in T cells compared to total exosomes of low stage patients (Figure 3B). 
This stage-dependent apoptosis was reflected in the CD45(−) exosome fractions. In contrast, CD45(+) 
exosomes showed a stage independent induction of apoptosis (Figure 3C). Comparing the induction 
of apoptosis by CD45(−) and CD45(+) exosomes of high stage patients, no significant difference was 
visible with both fractions inducing similar levels of apoptosis. In contrast, the CD45(+) fraction of 
low stage patients induced higher levels of apoptosis compared to the TEX-enriched fraction (Figure 
3C). Figure 3D presents exemplary flow cytometry plots, visualizing the difference between 
apoptosis induction by total exosomes of UICC low and high stage patients.  
  
Figure 2. Exosomal protein concentration. (A) Protein concentration of total exosomes from plasma
of high and low stage HNSC patients, n = 30 (B) CD45(−) exosome fraction of high and low stage
patients, n = 29. p values were determined with Mann-Whitney test, with * p < 0,05, **** p < 0,0001.
Bars represent mean with standard deviation (SD).
2.4. Induction of Apoptosis in Activated CD8+ T Cells by Plasma-Derived Exosomes
Induction of apoptosis in activated CD8+ T cells by plasma-derived exosomes of high and low
stage patients was tested. Incubation with total exosomes of HNSCC patients induced significant levels
of apoptosis compared to no-exosome controls, which was confirmed in this study (Figure 3A). When
incubating activated CD8+ T cells with exosomes of UICC high and low stage patients, significant
differences in apoptosis were visible. Total exosomes of high stage patients induced significantly more
apoptosis in T cells compared to total exosomes of low stage patients (Figure 3B). This stage-dependent
apoptosis was reflected in the CD45(−) exosome fractions. In contrast, CD45(+) exosomes showed
a stage independent induction of apoptosis (Figure 3C). Comparing the induction of apoptosis by
CD45(−) and CD45(+) exosomes of high stage patients, no significant difference was visible with both
fractions inducing similar levels of apoptosis. In contrast, the CD45(+) fraction of low stage patients
induced higher levels of apoptosis compared to the TEX-enriched fraction (Figure 3C). Figure 3D
presents exemplary flow cytometry plots, visualizing the difference between apoptosis induction by
total exosomes of UICC low and high stage patients.
2.5. Suppression of CD8+ T Cell Activation by Plasma-Derived Exosomes
The induction of CD69 expression on cytotoxic CD8+ T cells as a marker of activation was evaluated
after incubation with exosomes. Incubation of CD8+ T cells with total exosomes of HNSCC patients
showed significant inhibition of CD69 expression (Figure 4A). Total exosomes showed significant
inhibition of CD69 expression. However, the CD45(−) exosome fraction induced an even higher
suppression of CD69 in CD8+ T cells in contrast to CD45(+) exosomes, which did not affect T cell
activation levels at all (Figure 4A). Only exosomes of high stage patients induced a significant reduction
of CD69 expression (Figure 4B). Looking at the subgroups no inhibitory influence of CD45(+) exosomes
on CD69 levels and, therefore, on CD8+ T cell activity was evident. Interestingly, CD45(−) fractions
of both low and high stage patients induced similar levels of CD69 inhibition (Figure 4C). Especially
CD45(+) and CD45(−) exosomes of low stage patients presented significantly different levels of CD69
suppression (Figure 4C). Exemplary flow cytometry histograms are shown in Figure 4D.
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Figure 3. Induction of apoptosis in activated CD8+ T cells. (A) Induction of apoptosis after incubation 
with total exosome fractions. (B) Induction of apoptosis after incubation with total exosomes of low 
stage vs. high stage patients. (C) Levels of apoptosis after co-incubation with CD45(−) or CD45(+) 
exosomes of low or high stage patients. Note that only CD45(−) exosomes induced stage-dependent 
apoptosis, whereas CD45(+) exosomes showed no significant difference between stages. CD45 (+) 
exosomes of low stage patients induced more apoptosis than CD45(−) exosomes, whereas no 
significant difference was visible between those of high stage patients; n = 29. p values were 
determined with Mann-Whitney test, with * p < 0.05, **** p < 0.0001. Bars represent mean with 
standard deviation (SD). (D) Representative flow cytometry plots depicting CD8+ T cells stained with 
Annexin/Propidium Iodide (PI) after incubation with total and CD45(−) exosomes of Union for 
International Cancer Control (UICC) low or high stage patients. 
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evaluated after incubation with exosomes. Incubation of CD8+ T cells with total exosomes of HNSCC 
patients showed significant inhibition of CD69 expression (Figure 4A). Total exosomes showed 
significant inhibition of CD69 expression. However, the CD45(−) exosome fraction induced an even 
higher suppression of CD69 in CD8+ T cells in contrast to CD45(+) exosomes, which did not affect T 
cell activation levels at all (Figure 4A). Only exosomes of high stage patients induced a significant 
reduction of CD69 expression (Figure 4B). Looking at the subgroups no inhibitory influence of 
CD45(+) exosomes on CD69 levels and, therefore, on CD8+ T cell activity was evident. Interestingly, 
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Figure 3. Induction of apoptosis in activated CD8+ T cells. (A) Induction of apoptosis after incubation
with total exosome fractions. (B) Induction of apoptosis after incubation with total exosomes of low
stage vs. high stage patients. (C) Levels of apoptosis after co-incubation with CD45(−) or CD45(+)
exosomes of low or high stage patients. Note that only CD45(−) exosomes induced stage-dependent
apoptosis, whereas CD45(+) exosomes showed no significant difference between stages. CD45 (+)
exosomes of low stage patients induced more apoptosis than CD45(−) exosomes, whereas no significant
difference was visible between those of high stage patients; n = 29. p values were determined with
Mann-Whitney test, with * p < 0.05, **** p < 0.0001. Bars represent mean with standard deviation
(SD). (D) Representative flow cytometry plots depicting CD8+ T cells stained with Annexin/Propidium
Iodide (PI) after incubation with total and CD45(−) exosomes of Union for International Cancer Control
(UICC) low or high stage patients.
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Figure 4. CD69 expression by activated CD8+ T cells. (A) CD69 expression after incubation with total, 
CD45(−) and CD45(+) exosome fraction of patients of all stages (B) CD69 expression after incubation 
with total exosomes of low stage vs. high stage patients. (C) Incubation of CD8+ T cells with CD45(−) 
or CD45(+) exosomes of low or high stage patients.; n = 29. p values were determined with Mann-
Whitney test, with * p < 0.05, ** p < 0.005, *** p < 0.0005. Bars represent mean with standard deviation 
(SD). (D) Representative flow cytometry histograms depicting CD69 levels on CD8+ T cells after 
incubation with phosphate-buffered saline (PBS), total, CD45(−), and CD45(+) exosomes (left to right) 
are shown. The solid line represents the CD69 signal, the dashed line represents the unstained control. 
The respective CD69 positive signal is displayed in percent. 
2.6. Induction of CD39+ Treg Differentiation  
It was previously reported that exosomes from HNSCC upregulated CD39 expression 
dependent on their immunoinhibitory molecular content [20]. We confirmed CD39 induction on 
CD4+ T cells by total exosomes (Figure 5A). Furthermore, a stage-dependent induction of CD39 was 
visible (Figure 5B), with total exosomes of UICC high stage patients inducing significantly more CD39 
than those of low stage patients (Figure 5B). When evaluating the CD39 induction by exosome 
subpopulations, the CD45(+) fraction induced stage-independent low levels of CD39 expression, 
whereas the CD45(−) high stage fraction induced a relevant increase in CD39 (Figure 5C). Exemplary 
flow cytometry plots are visible in Figure 5D visualizing the difference between CD39 induction on 
CD4+ T cells by CD45(+) and CD45(−) exosomes of UICC low and high stage patients. 
Figure 4. 69 activated CD8+ T cells. (A) CD69 expression after incubation with
total, CD45(−) and CD45(+) exosome fraction of patients of all stages (B) CD69 expr ssion af er
incuba ion with total exosomes of low stage vs. high s age patients. (C) Incubation of CD8+ T cells
with CD45(−) or CD45(+) exos mes of low or high stage patients.; n = 29. p valu s were determined
with Mann-Whitney test, with * p < 0.05, ** p < 0.005, *** p < 0.0005. Bars represent mean with stand rd
deviation (SD). (D) Representative fl w cytometry histograms depicting CD69 levels on CD8+ T cells
after incubation with phosphate-buffered saline (PBS), total, CD45(−), and CD45(+) exosomes (left to
right) are shown. The solid line represents the CD69 signal, the ashed line represents the unstained
control. The respective CD69 positive signal is displayed in percent.
2.6. Induction of CD39+ Treg Differentiation
It was previously reported that exosomes from HNSCC upregulated CD39 expression dependent
on their immunoinhibitory molecular content [20]. We confirmed CD39 induction on CD4+ T cells by
total exosomes (Figure 5A). Furthermore, a stage-dependent induction of CD39 was visible (Figure 5B),
with total exosomes of UICC high stage patients inducing significantly more CD39 than those of low
stage patients (Figure 5B). When evaluating the CD39 induction by exosome subpopulations, the
CD45(+) fraction induced stage-independent low levels of CD39 expression, whereas the CD45(−)
high stage fraction induced a relevant increase in CD39 (Figure 5C). Exemplary flow cytometry plots
are visible in Figure 5D visualizing the difference between CD39 induction on CD4+ T cells by CD45(+)
and CD45(−) exosomes of UICC low and high stage patients.
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Figure 5. Induction of CD39+ Treg differentiation by plasma-derived exosomes. (A) Expression of 
CD39 after incubation with total exosome fraction of patients of all stages (B) Expression of CD39 
after incubation with total exosomes of low stage vs. high stage patients. (C) Expression of CD39 after 
incubation with CD45(−) and CD45(+) exosomes of low stage and high stage patients. Note that only 
incubation with CD45(−) exosomes showed significant stage-dependent differences.; n = 18. p values 
were determined with Mann-Whitney test, with * p < 0.05, ** p < 0.005, **** p < 0.0001. Bars represent 
standard error of mean (SEM). (D) Representative flow cytometry plots depicting CD39 expression of 
CD4+ T cells after incubation with CD45(−) (left) or CD45(+) (right) exosomes of UICC low stage (top) 
or high stage (bottom) patients. 
2.7. Production of Adenosine by Plasma-Derived Exosome Populations 
It has been shown previously that exosomes are independent producers of adenosine and other 
nucleosides due to the presence of CD39 and CD73 on their surface [8,13,20]. Here, we evaluated the 
nucleoside production by exosomes of different fractions and tumor stage. Figure 6A shows a tumor-
stage independent nucleoside production of total exosomes. No significant difference in production 
of inosine and hypoxanthine was visible. CD45(−) exosomes showed significantly lower 5′AMP levels 
than CD45(+) and total exosomes. Total and CD45(−) exosomes produced higher adenosine levels 
compared to CD45(+) exosomes, concluding that the majority of adenosine production derives from 
the CD45(−), TEX-enriched, fraction. No significant differences were visible when stratifying patients 
according to their tumor stage (Figure 6B). 
Figure 5. Induction of CD39+ Treg differentiation by plasma-derived exosomes. (A) Expression of
CD39 after incubation with total exosome fraction of patients of all stages (B) Expression of CD39 after
incubation with total exosomes of low stage vs. high stage patients. (C) Expression of CD39 after
incubation with CD45(−) and CD45(+) exosomes of low stage and high stage patients. Note that only
incubation with CD45(−) exosomes showed significant stage-dependent differences.; n = 18. p values
were determined with Mann-Whitney test, with * p < 0.05, ** p < 0.005, **** p < 0.0001. Bars represent
standard error of mean (SEM). (D) Representative flow cytometry plots depicting CD39 expression of
CD4+ T cells after incubation with CD45(−) (left) or CD45(+) (right) exosomes of UICC low stage (top)
or high stage (bottom) patients.
2.7. Production of Adenosine by Plasma-Derived Exosome Populations
It has been shown previously that exosomes are independent producers of adenosine and other
nucleosides due to the presence of CD39 and CD73 on their surface [8,13,20]. Here, we evaluated
the nucleoside production by exosomes of different fractions and tumor stage. Figure 6A shows
a tumor-stage independent nucleoside production of total exosomes. No significant difference in
production of inosine and hypoxanthine was visible. CD45(−) exosomes showed significantly lower
5′AMP levels than CD45(+) and total exosomes. Total and CD45(−) exosomes produced higher
adenosine levels compared to CD45(+) exosomes, concluding that the majority of adenosine production
derives from the CD45(−), TEX-enriched, fraction. No significant differences were visible when
stratifying patients according to their tumor stage (Figure 6B).
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(−) exosome fractions. The different exosome fractions showed significant differences between 5′AMP 
and adenosine production; n = 18; (B) Production of nucleosides in ng/mL by total exosomes 
comparing UICC low and high stage patients; n = 19. Mann-Whitney with * p < 0.05, *** p < 0.005, bars 
represent standard error of mean (SEM). 
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As exosomes isolated from plasma are a mix of extracellular vesicles originating from numerous 
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fractions is not possible. However, exosomes are likely to express markers of their parent cell, aiding 
in the selection of specific subpopulations. With bead-based immunoaffinity selections the separation 
of various subpopulations is possible, including CD3(+) T cell-derived, CD45(+) hematopoietic-
derived and CD45(−), or CD44v3(+) TEX-enriched fractions [20,25]. Here, we used our previously 
developed immune capture approach based on CD45 separation to enrich TEX and analyze their 
immune-modulatory effects compared to the CD45(+) fraction.  
We were able to confirm previous findings showing elevated protein levels in exosome samples 
of HNSCC patients and a correlation with tumor stage [13], but not only for total exosome samples 
but also for CD45(−) exosomes (Figure 2). This corroborates the hypothesis that CD45(−) exosomes 
are highly enriched in TEX, quantitatively representing the tumor stage of the patient and suggesting 
possible clinical applications as a diagnostic biomarker. 
Since a strong presence of CD8+ T cells in the TME is generally associated with a better prognosis 
[26,27] and intra-tumoral accumulation of Treg predicts resistance to treatments and accelerated cancer 
Figure 6. Production of nucleosides by exosomes of all stages. (A) Respectively, 5′ adenosine
monophosphate (5′AMP), Adenosine, Inosine, and Hypoxanthine production by total, CD45(+) and (−)
exosome fractions. The different exosome fractions showed significant differences between 5′AMP and
adenosine production; n = 18; (B) Production of nucleosides in ng/mL by total exosomes comparing
UICC low and high stage patients; n = 19. Mann-Whitney with * p < 0.05, ** p < 0.005, bars represent
standard error of mean (SEM).
3. Discussion
As exosomes isolated from plasma are a mix of extracellular vesicles originating from numerous
different cells [24], the assignment of effects to a certain cellular subpopulation using total exosome
fractions is not possible. However, exosomes are likely to express markers of their parent cell,
aiding in the selection of specific subpopulations. With bead-based immunoaffinity selections
the separation of various subpopulations is possible, including CD3(+) T cell-derived, CD45(+)
hematopoietic-derived and CD45(−), or CD44v3(+) TEX-enriched fractions [20,25]. Here, we used our
previously developed immune capture approach based on CD45 separation to enrich TEX and analyze
their immune-modulatory effects compared to the CD45(+) fraction.
We were able to confirm previous findings showing elevated protein levels in exosome samples
of HNSCC patients and a correlation with tumor stage [13], but not only for total exosome samples
but also for CD45(−) exosomes (Figure 2). This corroborates the hypothesis that CD45(−) exosomes
are highly enriched in TEX, quantitatively representing the tumor stage of the patient and suggesting
possible clinical applications as a diagnostic biomarker.
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Since a strong presence of CD8+ T cells in the TME is generally associated with a better
prognosis [26,27] and intra-tumoral accumulation of Treg predicts resistance to treatments and
accelerated cancer progression [28], evaluation of regulating mechanisms of immune cell populations,
especially T cell fractions, remains important.
We and others have shown previously that total exosomes of HNSCC patients induce apoptosis
in activated CD8+ T cells [13,20]. Here, we showed a stage-dependent induction of apoptosis by
total exosome fraction and further showed a stage-dependent induction of apoptosis by CD45(−),
TEX-enriched exosomes (Figure 3). CD45(+) exosomes also induced apoptosis, which is in line with
previously published characteristics of CD3(+), T cell-derived exosomes [20]. Exosome-induced
apoptosis originated mainly from the CD45(+) fraction in low stage patients, whereas both, CD45(+)
as well as CD45(−) exosomes of high stage patients, induced similar levels of apoptosis. This might
be due to a higher, stage-dependent variability of immune-suppressive molecular cargo in CD45(−)
TEX-enriched exosomes as opposed to a more static molecular cargo of CD45(+) exosomes. These
findings are in line with the results of Ludwig et al. [13] showing increased Fas and FasL expression on
UICC high stage plasma-derived exosomes with increased induction of caspase 3/7 activity in CD8+ T
cells. The supposed differences between induction of apoptosis by CD45(+) exosomes of low stage
patients (Figure 3C) and the CD8+ T cell by CD69 induction (Figure 4C) might be due to simultaneous
expression of FasL and expression of CD3, as CD3 is a known inducer of CD69 expression upon T cell
receptor (TCR) engagement [29].
Besides tumor stage-dependent induction of apoptosis by CD45(−) exosomes, they were also
responsible for suppression of CD8+ T cell activation as reflected by a high suppression of CD69 on
activated CD8+ T cells (Figure 4). Confirming previous results, there was no CD69 suppression detected
by total exosomes of UICC low stage patients [14]. However, we found that the CD45(−) exosome
fraction suppressed T cell activation independently of tumor stage, indicating that CD69 suppression
is a more stationary effect, which is induced by all TEX. It is possible that CD45(+) exosomes, especially
those of UICC low stage patients, carry immune stimulatory molecules, which compensate for the
effects of CD45(−) exosomes [20]. We have previously shown that CD3(+) exosomes from UICC
low stage patients carried higher levels of immune-stimulatory molecules OX40 and lower levels of
immune-suppressive factors as cyclooxygenase-2 (COX-2) [20]. Similar results have been reported in
melanoma patients, with non-tumor-derived exosomes carrying a higher load of immune-stimulatory
molecules than tumor-derived exosomes [30].
In contrast to CD8+ T cells, which play an immune-supportive role in the TME,
adenosine-producing CD39+ and CD73+ Treg are important factors in the inhibition of anti-tumor
immunity and associated with poor outcome [8,9].
Exosomes were shown to be independent producers of adenosine by surface expression of
CD73 and CD39 and to induce differentiation of CD4+ T cells to CD39+ Treg [8,20,31], potentiating
immune suppression in the TME. Here, we showed that induction of CD39 on CD4+ T cells by total
plasma-derived exosomes was dependent on the tumor stage at which exosomes were isolated (Figure 5).
Even more, Treg differentiation was mainly caused by CD45(−) TEX-enriched exosomes. CD45(+)
exosomes did not show any effect on Treg differentiation independently of UICC stage. Especially
exosomes carrying highly immunosuppressive cargo were reported to induce CD39 expression on
CD4+ T cells [20], with the assumption that the cargo of CD45(−) exosomes of high stage patients is
especially enriched in immune-suppressive molecules, inhibiting an anti-tumor immune response in
the TME.
Not only CD4+ Treg but also exosomes themselves contribute to adenosine production in the
TME [32], as they have been shown to carry the enzymatically active ectonucleotidases CD39 and
CD73 and produce adenosine in the presence of exogenous ATP [8,31].
Significant differences in the production of adenosine were observed between total, CD45(+), and
CD45(−) exosomes regardless of UICC stage. CD45(+) exosomes produced significantly less adenosine
than CD45(−) and total exosomes, suggesting TEX as the main exosomal adenosine producers. Similar
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results were reported previously, showing a high adenosine production by CD3(−) TEX-enriched
exosomes in contrast to almost no production by CD3(+) T cell-derived exosomes [31]. However,
here we observed an even higher adenosine production by CD45(−) exosomes compared to CD3(−)
fractions [31]. This may be due to a higher TEX-ratio in the first group by the exclusion of all
hematopoietic cells compared to exclusion of only T cells in the CD3(−) fraction.
Due to their unique origin and molecular profiles, exosomes have emerged as potential biomarkers
in liquid biopsies [18,33]. Previously, not only the TEX-enriched fraction but also the immune
cell-derived fraction had been investigated as liquid biopsy markers as well as therapy monitoring
tools [13,31,34]. Our results and experience with the methodology concerning CD45(+) and CD45(−)
exosomes suggest that these fractions can very well be used in a clinical setting to monitor therapy
response during treatment as well as aid in staging procedures beforehand.
4. Materials and Methods
4.1. Patients
Aliquots of 1mL plasma samples, stored at −80 ◦C, from 41 HNSCC patients seen between
2014 and 2019 at the Department of ENT, Head and Neck Surgery, University of Ulm were used for
exosome isolation. The collection of blood samples and access to clinical data for research purposes
was approved by the Ulm University ethics committee under proposal number 90/15. Additionally,
blood of healthy controls was processed for T cell isolation.
4.2. Exosome Isolation by Mini Size Exclusion Chromatography (Mini-SEC)
Exosomes were isolated using the mini-SEC method, as previously established, optimized, and
described [13] (EV-TRACK ID: EV160007). Briefly, plasma samples were pre-cleared by centrifugation
at 2000 g and 100,000 g followed by ultrafiltration using a 0.22 µm filter [13]. 1mL of pre-cleared
plasma was placed on a mini-SEC column and eluted with phosphate-buffered saline (PBS). The 4th
void volume fraction enriched in intact and functionally active exosomes was collected as previously
described [13].
4.3. Characterization of Plasma-Derived Exosomes
The isolated exosomes were characterized according to MISEV 2018 standards [23] using (a)
nanoparticle tracking (NTA), (b) transmission electron microscopy (TEM), (c) and Western blot analysis.
4.3.1. Nanoparticle Tracking
NTA was performed using the Zeta View PMX-220 (Particle Metrix, Inning, Bayern, Germany).
Freshly isolated exosomes were diluted to a concentration of 1:100,000 in 1 mL PBS and loaded into the
cell. Measurements were taken at 11 different positions throughout the cell. At each position, three
cycles of records were taken. The instrument was operated at the following parameters: temperature of
25 ◦C, sensitivity of 85, and a shutter of 100. As a control, PBS and 100 nm polystyrene beads were used.
The nanoparticle size ranges and concentrations were calculated using ZetaView 8.05.11 software.
4.3.2. Transmission Electron Microscopy
Freshly isolated exosomes were layered on copper grids in a multi-step procedure and stained with
1% uranyl acetate in ddH2O. Immediate visualization by use of the transmission electron microscope
followed. Pictures of vesicles, diameters ranging from 40 to 160 nm, were taken.
4.3.3. Western Blot
Exosomes were lysed in Lane Marker Reducing Sample Buffer (Pierce, Thermo Scientific),
Waltham, MA, USA) separated on 12% SDS/PAGE gels (Bio-Rad, Hercules, CA, USA), always applying
10 µg protein per lane, and transferred onto a nitrocellulose membrane using the Transblot Turbo
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System (Bio-Rad). The membrane was incubated at 4 ◦C overnight with either TSG 101 antibody
(1:500, PA31260, Thermo Scientific), CD45 (1:50, MA5-13197, ThermoFisher Scientific), or Epithelial
cell adhesion molecule (EpCAM) (1:500, MA5-13917, ThermoFisher Scientific). After washing, a
corresponding secondary antibody (1:10,000, 31450 and 31460, anti-rabbit or anti-mouse, ThermoFisher
Scientific,) was added for 1 hour at room temperature (RT), and the membrane was developed
with Super Signal West Dura Extended Duration Kit (Thermo Scientific) and analyzed using a
ChemiDoc (BioRad).
4.4. BCA Protein Assay and Exosome Concentration
Pierce BCA protein assay kit (Pierce Biotechnology, Rockford, IL, USA) was used to determine the
protein concentration of the isolated exosome fraction #4, following the manufacturer’s instructions.
Concentration of exosomes was performed using centrifugal filters (cut-off 100kDa, Amicon Ultra by
Merck Millipore).
4.5. Separation of Total Exosomes Using Biotinylated CD45 Antibodies
Total exosomes were incubated with biotinylated CD45 Ab (clone H130, 304004 Bio Legend,
San Diego, CA, USA) at dilution of 1:25 for 16h on a shaker at 4 ◦C. Pre-washed ExoCap Beads
(Medical&Biological Laboratories Co. Ltd., Naka-ku, Nagoya, Aichi, Japan) were added to the sample
and incubated another 2h on the shaker at RT. Separation into CD45(−) and CD45(+), bead-bound,
exosome fractions was performed using a MagRack 6 magnetic stand (GE-Lifesciences, Chicago,
IL, USA).
4.6. Functional Assays
4.6.1. Apoptosis and CD69 Induction in CD8+ Cells by Patients’ Exosomes
CD8+ T cells (2 × 106/mL), isolated with CD8+ T cell isolation kit (17953, Stemcell Technologies,
Vancouver, Canada) according to manufacturer’s instructions, were activated using CD3/CD28 T-cell
activator (25 µL/mL, Stemcell Technologies) and 0.7 µL IL2 (2 × 105 U/ml, R&D Systems, Minneapolis,
MN, USA) in RPMI supplemented with exosome-depleted FBS (Gibco, Waltham, MA, USA) for 6
or 16h, respectively, for activation or apoptosis assay. Next, exosomes (50 µL of the total fraction,
CD45(+), or CD45(−) fraction) isolated from plasma of HNSCC patients were added and co-cultures
were incubated for 16 or 6h, respectively, for activation or apoptosis assay. Only the CD45(+) fraction
was bound on beads. Co-cultures containing no exosomes (50 µL PBS alone) or streptavidin beads with
biotinylated CD45Ab served as negative controls. Apoptosis of CD8+ T cells and CD69 expression
were measured by flow cytometry with a Gallios flow cytometer using an apoptosis assay kit (Annexin
V-FITC Apoptosis Staining/Detection Kit, Abcam, Cambridge, UK) and CD69-FITC antibody (555530,
BD Pharmingen, Franklin Lakes, NJ, USA), respectively. The protocol was previously described in
detail [14].
4.6.2. CD39 Induction in CD4+ T Cells by Patients’ Exosomes
Exosomes of HNSCC patients were co-incubated with healthy human CD4(+) T cells (105/100 µL)
in the presence of 20 µM of exogenous ATP (Sigma Life Science). Exosome samples used were derived
from the total, CD45(+), or CD45(−) fraction. The CD4(+) T cells were isolated using a CD4+ T cell
isolation kit (17952, Stemcell Technologies) according to manufacturer’s instruction. Control samples
incubated with no exosomes (PBS only) and without ATP were used.
After 20h of incubation, percentages of CD4+CD39+ T cells were determined by flow cytometry
using anti-CD4-FITC Ab (11-0049-42, eBioscience) and anti-CD39-PECy7 Ab (25-0399-42, eBioscience,
San Diego, CA, USA). The protocol was previously described in detail [8,20,31].
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4.6.3. Evaluation of Adenosine Production by Patients’ Exosomes
Total, CD45(−), and CD45(+) exosomes were concentrated to 10 µg in 100 µL and incubated with
20µM ATP for 1h at 37 ◦C. Exosomes without ATP or ATP alone were used as controls. All samples were
then centrifuged at 6000 g for 2 min at RT and boiled for 2 min at 95 ◦C. The samples were stored at −80
◦C until further processing. 5′-AMP, adenosine, and their degradation products inosine, hypoxanthine,
and xanthine were measured by mass spectrometry. Using liquid chromatography-tandem mass
spectrometry, the selected reaction with 13C10-adenosine as an internal standard was measured. 1%
acetic acid (mobile phase 1) and methanol (mobile phase 2) were used as mobile phases in differing
elution gradients. The mass spectrometer was outfitted with a heated electrospray ionization source
and operated in positive-ion mode. The method was previously described by our group [8,31].
4.7. Statistics
Statistical analysis was performed using Prism version 7 (Graphpad, San Diego, CA, USA). Scatter
dot plots depict mean and standard error of mean (SEM) or standard deviation (SD), as stated in the
figure legends. As a nonparametric test of unpaired values, the Mann-Whitney test was chosen. The
p-value of <0.05 was used to evaluate the significance of the data.
5. Conclusions
Exosomes derived from plasma of UICC high stage HNSCC patients showed higher
immune-suppressive effects than exosomes from plasma of UICC low stage patients. Furthermore, we
show for the first time that effects of CD45(−) and CD45(+) exosomes differ substantially, allowing
us to gain further insights into TEX- and non-TEX-mediated changes in the TME. Although CD45(+)
exosomes have an immune-suppressive potential, the highest immune suppression is caused by TEX.
Due to their origin and obviously distinguishing characteristics, CD45(−) TEX-enriched exosomes
can be considered as an easily accessible liquid biomarker for cancer aggressiveness in HNSCC.
Additionally, the CD45(+) hematopoietic exosomes can be used as a biomarker for immune suppression
in the TME.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/7/1997/s1,
Figure S1: Uncropped Western blots and densitometry results of Figure 1.
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